{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.60","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"PFS is defined as the duration from time of transplant Day 0 to time of first progression/clinical relapse, death, or the date the patient was last known to be in remission","groups":[{"description":"Granix on Day -7 through Day -2.\n\nHDM intravenously (IV) on Day -2.\n\nAutologous stem cell transplantation on Day 0","id":"OG000","title":"Experimental: Granix and High Dose Melphalan (HDM)"},{"description":"HDM intravenously (IV) on Day -2.","id":"OG001","title":"Control: High Dose Melphalan (HDM)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Progression-free Survival as Measured by Number of Participants Without Disease Progression at Last Follow-up","type":"SECONDARY","unitOfMeasure":"Participants"}